Celltrion Healthcare Co Ltd
KOSDAQ:091990

Watchlist Manager
Celltrion Healthcare Co Ltd Logo
Celltrion Healthcare Co Ltd
KOSDAQ:091990
Watchlist
Price: 75 900 KRW -5.6% Market Closed
Market Cap: 12.5T KRW
Have any thoughts about
Celltrion Healthcare Co Ltd?
Write Note
Celltrion Healthcare Co Ltd
/
Cash Flow Statement
/
Cash from Operating Activities

Celltrion Healthcare Co Ltd
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Celltrion Healthcare Co Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Celltrion Healthcare Co Ltd
KOSDAQ:091990
Cash from Operating Activities
-₩38.1B
CAGR 3-Years
42%
CAGR 5-Years
36%
CAGR 10-Years
N/A
C
Chorokbaem Healthcare Co Ltd
KRX:118000
Cash from Operating Activities
-₩12.9B
CAGR 3-Years
N/A
CAGR 5-Years
-37%
CAGR 10-Years
N/A
W
WSI Co Ltd
KOSDAQ:299170
Cash from Operating Activities
₩2.5B
CAGR 3-Years
21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
W
Wonik Co Ltd
KOSDAQ:032940
Cash from Operating Activities
₩7.6B
CAGR 3-Years
0%
CAGR 5-Years
7%
CAGR 10-Years
N/A
H
HLB Life Science Co Ltd
KOSDAQ:067630
Cash from Operating Activities
-₩28.1B
CAGR 3-Years
N/A
CAGR 5-Years
-28%
CAGR 10-Years
N/A
B
BlueMTec Co Ltd
KOSDAQ:439580
Cash from Operating Activities
-₩1.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Celltrion Healthcare Co Ltd
Glance View

Market Cap
12.2T KRW
Industry
Health Care

Celltrion Healthcare Co., Ltd. is a pioneering biopharmaceutical company based in South Korea, with a remarkable focus on developing and manufacturing innovative therapies that harness the power of biotechnology. Established in 2002, Celltrion has rapidly emerged as a leader in the biopharmaceutical industry, particularly known for its biosimilars and monoclonal antibody products. The company's mission is rooted in making high-quality medications more accessible and affordable on a global scale, targeting serious diseases such as cancer, autoimmune disorders, and infectious diseases. With a robust pipeline of biosimilar products aimed at offering effective alternatives to expensive biologics, Celltrion is strategically positioned to capitalize on the growing demand for cost-effective pharmaceutical solutions, especially as patent expirations of original biologics pave the way for increased competition in the market. What sets Celltrion apart is its commitment to research and development, supported by its state-of-the-art manufacturing facilities that comply with international quality standards. Its flagship products, including trastuzumab biosimilars, have already garnered approval and are being successfully marketed in multiple regions, including Europe and Asia. By leveraging cutting-edge biomanufacturing techniques and its extensive expertise, Celltrion not only reduces reliance on traditional pharmaceuticals but also addresses pressing healthcare needs globally. For investors, Celltrion presents a compelling opportunity as it continues to expand its global footprint, with increasing partnerships and collaborations aiming to unlock new markets and enhance shareholder value. As the biopharmaceutical landscape evolves, Celltrion’s innovative approach and steadfast growth trajectory position it as a formidable player, making it a company worth watching for anyone interested in the future of healthcare.

Intrinsic Value
64 279.29 KRW
Overvaluation 15%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Celltrion Healthcare Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
-38.1B KRW

Based on the financial report for Jun 30, 2023, Celltrion Healthcare Co Ltd's Cash from Operating Activities amounts to -38.1B KRW.

What is Celltrion Healthcare Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
36%

The average annual Cash from Operating Activities growth rates for Celltrion Healthcare Co Ltd have been 42% over the past three years , 36% over the past five years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 204,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.